Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team

Friday, October 3, 2008 General News J E 4
PARSIPPANY, N.J., Oct. 2 Pacira Pharmaceuticals, Inc., anacute care specialty pharmaceutical company, today announced the addition of akey senior executive to the company's management team. David St. Peter, M.D.joins Pacira as Vice President of Medical Education and Scientific Affairs.Dr. St. Peter was previously with inVentiv Health where he held several seniormanagement positions since 2001, most recently serving on their Executive Teamas president of The Selva Group, LLC, a medical education and event managementcompany. In addition to industry positions at Marion Merrell Dow and Merck,Sharp & Dohme, he is in private practice and continues to see patients in theacute care setting as a Hospitalist.


"Dr. St. Peter brings a clear understanding of the critical elementsrequired for successful late-phase market development in the institutionalsetting. In addition to working closely with our R&D, clinical and commercialteams as we prepare for a successful launch of DepoBupivacaine, we expect hiscontributions to be broad-based throughout Pacira's overall commercialprogram," commented chief executive officer Dave Stack.

Dr. St. Peter holds an M.D. from Kansas University Medical Center and aB.S. from the University of Kansas. He completed an internship in surgery atthe University of Missouri and St. Lukes Hospital and a residency in medicineat Baptist Medical Center. He is an active member of the AMA, Society ofHospital Medicine, ACRP, APPI, AAFP, Alpha Omega Alpha, Global Alliance forMedical Education (GAME) and the American Medical Writers Association. St.Peter holds active medical licenses in two states and is board certified.

About Pacira

Pacira is an acute care specialty pharmaceutical company with a primaryfocus on developing products which satisfy the needs of our customers in theinstitutional marketplace. The Company utilizes DepoFoam(R) deliverytechnology to cost-effectively improve patient care through enhanced dosingand administration profiles. Currently, the Company is developingDepoBupivacaine(TM) in phase III clinical studies for postsurgical pain.Revenues are generated from two approved products which are marketed bypartners: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) forpost-surgical pain. Additional information about Pacira is available at

This press release contains forward looking statements, which involverisks and uncertainties within the meaning of the Private SecuritiesLitigation Reform Act of 1995. There can be no assurance that actual resultswill not differ materially from the forward looking statements discussed inthis press release. These forward looking statements include risks anduncertainties that current or future collaboration will prove to becommercially successful.

Contact: Taunia Markvicka908-930-4995

SOURCE Pacira Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
InterCure Ranked #1 Website in Hitwise U.S. Top 10...
The CAMRIS International and Global Med Technologi...